Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years
- PMID: 30885997
- PMCID: PMC6436016
- DOI: 10.1182/bloodadvances.2018025890
Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years
Abstract
Osteopetrosis (OP) is a rare disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available in the infantile "malignant" form of OP. Improved clinical and genetic diagnosis of OP has seen the emergence of a cohort of patients with less severe and heterogeneous clinical presentations. This intermediate form of OP does not call for urgent intervention, but patients accumulate debilitating skeletal complications over years and decades, which are severe enough to require curative treatment and may also require intermittent transfusion of blood products. Here we present data from 7 patients with intermediate OP caused by mutations in TCIRG1 (n = 2), CLCN7 (n = 2), RANK (n = 1), SNX10 (n = 1), and CA2 (n = 1), who were transplanted between the ages of 5 to 30 years (mean, 15; median, 12). Donors were matched siblings or family (n = 4), matched unrelated (n = 2), or HLA haploidentical family donors (n = 1). Conditioning was fludarabine and treosulfan based. All 6 patients transplanted from matched donors are currently alive with a follow-up period between 1 and 8 years at time of publication (median, 4 years) and have demonstrated a significant improvement in symptoms and quality of life. Patients with intermediate OP should be considered for HSCT.
© 2019 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures


Similar articles
-
Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.Pediatr Transplant. 2015 Jun;19(4):422-7. doi: 10.1111/petr.12476. Epub 2015 Apr 16. Pediatr Transplant. 2015. PMID: 25879376
-
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.Pediatr Blood Cancer. 2018 Jun;65(6):e27010. doi: 10.1002/pbc.27010. Epub 2018 Feb 22. Pediatr Blood Cancer. 2018. PMID: 29469225
-
[Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China].Zhonghua Er Ke Za Zhi. 2012 Nov;50(11):807-12. Zhonghua Er Ke Za Zhi. 2012. PMID: 23302608 Chinese.
-
How we approach malignant infantile osteopetrosis.Pediatr Blood Cancer. 2021 Mar;68(3):e28841. doi: 10.1002/pbc.28841. Epub 2020 Dec 12. Pediatr Blood Cancer. 2021. PMID: 33314591 Review.
-
Autosomal recessive osteopetrosis: mechanisms and treatments.Dis Model Mech. 2021 May 1;14(5):dmm048940. doi: 10.1242/dmm.048940. Epub 2021 May 10. Dis Model Mech. 2021. PMID: 33970241 Free PMC article. Review.
Cited by
-
Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa.Cureus. 2022 Jul 6;14(7):e26600. doi: 10.7759/cureus.26600. eCollection 2022 Jul. Cureus. 2022. PMID: 35936184 Free PMC article. Review.
-
Origin of Osteoclasts: Osteoclast Precursor Cells.J Bone Metab. 2023 May;30(2):127-140. doi: 10.11005/jbm.2023.30.2.127. Epub 2023 May 31. J Bone Metab. 2023. PMID: 37449346 Free PMC article.
-
SNX10 gene mutation in infantile malignant osteopetrosis: A case report and literature review.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jan 28;46(1):108-112. doi: 10.11817/j.issn.1672-7347.2021.190322. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021. PMID: 33678645 Free PMC article. Review. Chinese, English.
-
Metabolic bone disorders and the promise of marine osteoactive compounds.Cell Mol Life Sci. 2023 Dec 20;81(1):11. doi: 10.1007/s00018-023-05033-x. Cell Mol Life Sci. 2023. PMID: 38117357 Free PMC article. Review.
-
Correction of osteopetrosis in the neonate oc/oc murine model after lentiviral vector gene therapy and non-genotoxic conditioning.Front Endocrinol (Lausanne). 2024 Sep 9;15:1450349. doi: 10.3389/fendo.2024.1450349. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39314524 Free PMC article.
References
-
- Sobacchi C, Schulz A, Coxon FP, Villa A, Helfrich MH. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-536. - PubMed
-
- Fasth A, Porras O. Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant. 1999;3(suppl 1):102-107. - PubMed
-
- Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-2849. - PubMed
-
- Whyte MP. Sclerosing bone disorders. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. New York: Lippincott Willians & Wilkins; 1999:367-383.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous